Pharma Focus Asia
KP - Choose our fully recyclable blister films

Jardiance® Novel Therapy Developed for the Treatment of Patients with Heart Failure

Eli Lilly and Company in combination with Boehringer Ingelheim has developed Jardiance®, a novel therapy to treat patients with heart failure with preserved ejection fraction (HFpEF).

Jardiance is used to lower the blood sugar levels along with diet and exercise in adults with type 2 diabetes, lessens the risk of cardiovascular death in adults with type 2 diabetes and also reduces the risk of hospitalisation for heart failure.

In EMPEROR-Preserved phase III trial, Jardiance has shown 21 per cent of risk reduction of cardiovascular death or hospitalisation for heart failure adults with preserved ejection fraction when compared with placebo.

Some of the common side effects caused by Jardiance® are Ketoacidosis, Dehydration, severe urinary tract infections, low blood sugar, Necrotizing fasciitis, Vaginal yeast infection and allergy.

U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy designation for Jardiance® (empagliflozin) to treat adults with HFpEF.

In US, HFpEF leads for more than 6 million heart failure cases. Currently there are no treatments available which shows significant improvement for patients with HFpEF.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023
MasterControl - 6 Essential Features in an eQMS